Abstract
AR-42, a new orally bioavailable, potent, hydroxamate-tethered phenylbutyrate class I/IIB histone deacetylase inhibitor currently is under evaluation in phase 1 and 2 clinical trials and has demonstrated activity in both hematologic and solid tumor malignancies. This report focuses on the preclinical characterization of the pharmacokinetics of AR-42 in mice and rats. A high-performance liquid chromatography–tandem mass spectrometry assay has been developed and applied to the pharmacokinetic study of the more active stereoisomer, S-AR-42, when administered via intravenous and oral routes in rodents, including plasma, bone marrow, and spleen pharmacokinetics (PK) in CD2F1 mice and plasma PK in F344 rats. Oral bioavailability was estimated to be 26 and 100% in mice and rats, respectively. R-AR-42 was also evaluated intravenously in rats and was shown to display different pharmacokinetics with a much shorter terminal half-life compared to that of S-AR-42. Renal clearance was a minor elimination pathway for parental S-AR-42. Oral administration of S-AR-42 to tumor-bearing mice demonstrated high uptake and exposure of the parent drug in the lymphoid tissues, spleen, and bone marrow. This is the first report of the pharmacokinetics of this novel agent, which is now in early phase clinical trials.
Similar content being viewed by others
References
Meinke PT, Liberator P. Curr Med Chem. 2001;8:211.
Monneret C. Eur J Med Chem. 2005;40:1.
Kouraklis G, Theocharis S. Curr Med Chem Anticancer Agents. 2002;2:477.
Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Proc Natl Acad Sci U S A. 2003;100:2041.
Richon VM, Zhou X, Rifkind RA, Marks PA. Blood Cells Mol Dis. 2001;27:260.
Johnstone RW. Nat Rev Drug Discov. 2002;1:287.
Lu Q, Yang Y-T, Chen C-S, Davis M, Byrd JC, Etherton MR, et al. J Med Chem. 2004;47:467.
Marks PA, Richon VM, Rifkind RA. J Natl Cancer Inst. 2000;92:1210.
Chen C-S, Weng S-C, Tseng P-H, Lin H-P, Chen C-S. J Biol Chem. 2005;280:38879.
Jung M. Curr Med Chem. 2001;8:1505.
Kulp SK, Chen C-S, Wang D-S, Chen C-Y, Chen C-S. Clin Cancer Res. 2006;12:5199.
Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. Cancer Res. 2001;61:8492.
Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, et al. J Med Chem. 2005;48:1019.
Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, et al. J Natl Cancer Inst. 2004;96:1447.
Bouchain G, Delorme D. Curr Med Chem. 2003;10:2359.
Wittich S, Scherf H, Xie C, Brosch G, Loidl P, Gerhaeuser C, et al. J Med Chem. 2002;45:3296.
Wang D-F, Wiest O, Helquist P, Lan-Hargest H-Y, Wiech NL. Bioorg Med Chem Lett. 2004;14:707.
Lu Q, Wang D-S, Chen C-S, Hu Y-D, Chen C-S. J Med Chem. 2005;48:5530.
Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, et al. Oncotarget. 2015;6:31134.
Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS. J Natl Cancer Inst. 2015;107.
Hofmeister CC, Liu ZF, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DM, Andritsos LA, Greenfield CN, Sell M, Geyer S, Byrd JC, Grever MR. Blood 2012;120.
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, et al. Leukemia. 2013;27:871.
Guidance for Industry, Bioanalytical Method Validation. Draft Guidance. U.S. Department of Health and Human Services, Food and Drug Administration. September, 2013. Revision 1.
Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, et al. Cancer Res. 2008;68:3999.
Acknowledgments
This study is supported by NCI-N01-CM-52205 (KKC) and NCI-RO1-CA158350 (RG). This work has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Hao Cheng and Zhiliang Xie contributed equally to this work.
Rights and permissions
About this article
Cite this article
Cheng, H., Xie, Z., Jones, W.P. et al. Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. AAPS J 18, 737–745 (2016). https://doi.org/10.1208/s12248-016-9876-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-016-9876-3